<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04141930</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00008200</org_study_id>
    <nct_id>NCT04141930</nct_id>
  </id_info>
  <brief_title>Pilot of Cohort of Households for Influenza Monitoring and Evaluation in Seattle</brief_title>
  <acronym>pCHIMES</acronym>
  <official_title>Pilot of Cohort of Households for Influenza Monitoring and Evaluation in Seattle (pCHIMES)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate a home-based approach to influenza infection control, using&#xD;
      prepositioned home-based influenza self-test kits, telemedicine services, and rapid delivery&#xD;
      of Xofluza (Baloxavir marboxil) for administration within 48 hours of symptom onset.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Households represent an important location for transmission of influenza. Rapid delivery of&#xD;
      Xofluza may reduce household exposures to influenza among susceptible individuals.This study&#xD;
      is a pilot study of a home-based approach to influenza infection control, utilizing self-test&#xD;
      kits and rapid home delivery of an antiviral. Households with at least 3 individuals residing&#xD;
      there at least 4 days a week, including at least 2 household members that are eligible to&#xD;
      take antiviral, will be monitored throughout the influenza season for the onset of a cough or&#xD;
      two or more acute respiratory infection symptoms. This study will be conducted in households&#xD;
      in the Seattle, WA area for one influenza season, beginning November 1, 2019 and ending April&#xD;
      1, 2020. Household will self-monitor for onset of symptoms throughout the influenza season.&#xD;
      When symptoms develop, the participant will self-test for influenza infection using a&#xD;
      prepositioned home-testing kit. If negative, the ill participant will provide one&#xD;
      self-collected nasal swab specimen. If positive, the ill participant will connect with a&#xD;
      healthcare provider via the tele-health app on their smartphone to confirm the influenza&#xD;
      diagnosis. Next, if eligible to receive Xofluza, the influenza-positive individual will&#xD;
      receive a rapid home delivery of Xofluza within 2-6 hours of the positive test result. All&#xD;
      influenza-positive participants will provide a self-collected nasal swab specimen at Study&#xD;
      Day 0, Study Day 2-3, and Study Day 5-7. For all illness episodes, the ill individual will&#xD;
      complete a questionnaire regarding symptom duration and severity, as well as behavioral&#xD;
      changes due to illness.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Actual">April 1, 2020</completion_date>
  <primary_completion_date type="Actual">April 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Initiate Antiviral Therapy Within 48 Hours of Symptom Onset</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Among symptomatic participants, this outcome measure will be calculated by determining the number of home influenza test-positive, drug eligible participants that were prescribed and rapidly delivered baloxavir by the study within 48 hours of symptom onset.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Home Influenza Tests Confirmed by Laboratory Testing</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Proportion of individuals who test positive for influenza using the home-based influenza test compared to the number of individuals that test positive for influenza via a PCR laboratory test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delivered Antivirals Within 48 Hours of Symptom Onset</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Proportion of individuals who are delivered antivirals within 48 hours of symptom onset. Only drug eligible study participants prescribed an antiviral</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">481</enrollment>
  <condition>Influenza</condition>
  <condition>Respiratory Viral Infection</condition>
  <arm_group>
    <arm_group_label>Study Drug Eligible</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Baloxavir given in 40 mg and 80 mg tablets for single-dose oral consumption during the first influenza infection for that participant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baloxavir Marboxil</intervention_name>
    <description>Individuals willing and able, will receive a weight-based oral dose of baloxavir within 48 hours of symptom onset</description>
    <arm_group_label>Study Drug Eligible</arm_group_label>
    <other_name>Xofluza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Household Level:&#xD;
&#xD;
          -  Group of at least 3 individuals of any ages defined as at least 3 persons residing at&#xD;
             the same address for at least 4 days per calendar week&#xD;
&#xD;
          -  Household group utilizes common household areas&#xD;
&#xD;
          -  At least 2 household members meeting all individual inclusion/exclusion criteria&#xD;
             listed below and willing to participate (e.g. at least two members of the household&#xD;
             are 12 years of age or older)&#xD;
&#xD;
          -  At least one member of the household has a smartphone&#xD;
&#xD;
          -  Individual Level: Drug Eligible&#xD;
&#xD;
          -  Resident of a household with 3 or more members (including eligible cases) for 4 or&#xD;
             more days a calendar week&#xD;
&#xD;
          -  Age 12 years or older weighing at least 40 kg (greater than 88 pounds)&#xD;
&#xD;
          -  Willing and able to take study medication&#xD;
&#xD;
          -  Willing to comply with all study procedures&#xD;
&#xD;
          -  English-speaking&#xD;
&#xD;
          -  Able to provide written, informed consent and/or assent (if applicable)&#xD;
&#xD;
          -  Permanent mailing address that is available for study staff to mail necessary&#xD;
             materials&#xD;
&#xD;
          -  Individual Level: Drug Ineligible&#xD;
&#xD;
          -  Resident of a household with 3 or more members (including eligible cases) for 4 or&#xD;
             more days a calendar week&#xD;
&#xD;
          -  Willing to comply with all study procedures&#xD;
&#xD;
          -  English-speaking&#xD;
&#xD;
          -  Able to provide written, informed consent and/or assent (if applicable)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Household Level:&#xD;
&#xD;
          -  Previous documentation of an influenza infection prior to or during the annual&#xD;
             influenza season in any household member prior to enrollment&#xD;
&#xD;
          -  Individual Level:&#xD;
&#xD;
          -  Any serious or uncontrolled medical disorder or active infection that, in the opinion&#xD;
             of the investigator, may increase the risk associated with study participation or&#xD;
             study drug administration&#xD;
&#xD;
          -  Individuals with hypersensitivity to baloxavir&#xD;
&#xD;
          -  Individuals that already have a tele-health account&#xD;
&#xD;
          -  Any individual that has one or more of the following conditions:&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  Currently lactating&#xD;
&#xD;
          -  Immunosuppressed or immunocompromised (by disease or medication)&#xD;
&#xD;
          -  Cancer&#xD;
&#xD;
          -  Liver disease&#xD;
&#xD;
          -  Kidney disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helen Y Chu, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, Ishida T, Sekino H, Yamada K, Portsmouth S, Kawaguchi K, Shishido T, Arai M, Tsuchiya K, Uehara T, Watanabe A; Baloxavir Marboxil Investigators Group. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N Engl J Med. 2018 Sep 6;379(10):913-923. doi: 10.1056/NEJMoa1716197.</citation>
    <PMID>30184455</PMID>
  </reference>
  <reference>
    <citation>Hayden FG, Belshe R, Villanueva C, Lanno R, Hughes C, Small I, Dutkowski R, Ward P, Carr J. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis. 2004 Feb 1;189(3):440-9. Epub 2004 Jan 26.</citation>
    <PMID>14745701</PMID>
  </reference>
  <reference>
    <citation>Welliver R, Monto AS, Carewicz O, Schatteman E, Hassman M, Hedrick J, Jackson HC, Huson L, Ward P, Oxford JS; Oseltamivir Post Exposure Prophylaxis Investigator Group. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA. 2001 Feb 14;285(6):748-54.</citation>
    <PMID>11176912</PMID>
  </reference>
  <reference>
    <citation>Leung YH, Li MP, Chuang SK. A school outbreak of pandemic (H1N1) 2009 infection: assessment of secondary household transmission and the protective role of oseltamivir. Epidemiol Infect. 2011 Jan;139(1):41-4. doi: 10.1017/S0950268810001445. Epub 2010 Jun 21.</citation>
    <PMID>20561390</PMID>
  </reference>
  <reference>
    <citation>Fry AM, Goswami D, Nahar K, Sharmin AT, Rahman M, Gubareva L, Azim T, Bresee J, Luby SP, Brooks WA. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. Lancet Infect Dis. 2014 Feb;14(2):109-18. doi: 10.1016/S1473-3099(13)70267-6. Epub 2013 Nov 22.</citation>
    <PMID>24268590</PMID>
  </reference>
  <reference>
    <citation>Takashita E, Ichikawa M, Morita H, Ogawa R, Fujisaki S, Shirakura M, Miura H, Nakamura K, Kishida N, Kuwahara T, Sugawara H, Sato A, Akimoto M, Mitamura K, Abe T, Yamazaki M, Watanabe S, Hasegawa H, Odagiri T. Human-to-Human Transmission of Influenza A(H3N2) Virus with Reduced Susceptibility to Baloxavir, Japan, February 2019. Emerg Infect Dis. 2019 Nov;25(11):2108-2111. doi: 10.3201/eid2511.190757. Epub 2019 Nov 17.</citation>
    <PMID>31436527</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 23, 2019</study_first_submitted>
  <study_first_submitted_qc>October 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2019</study_first_posted>
  <results_first_submitted>April 2, 2021</results_first_submitted>
  <results_first_submitted_qc>July 13, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 5, 2021</results_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Helen Chu</investigator_full_name>
    <investigator_title>Assistant Professor, School of Medicine: Allergy and Infectious Diseases</investigator_title>
  </responsible_party>
  <keyword>influenza</keyword>
  <keyword>flu</keyword>
  <keyword>antiviral</keyword>
  <keyword>baloxavir</keyword>
  <keyword>Xofluza</keyword>
  <keyword>rapid delivery</keyword>
  <keyword>self-test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Baloxavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We do not currently expect to share specimens with outside investigators, but if compelling opportunities arise that will advance the overall objectives of this research, the Executive Committee of the study will consider such requests. They alone have the authority to make such decisions.&#xD;
All biospecimens (nasal swabs) will be coded and identifiable through the study's main database. Any specimens shared with external investigators (if deemed appropriate by the Executive Committee) will have identifiers removed prior to sharing.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 14, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT04141930/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 8, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT04141930/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Study Drug Eligible</title>
          <description>Baloxavir given in 40 mg and 80 mg tablets for single-dose oral consumption during the first influenza infection for that participant. Individuals need to be eligible based on on-label use according to their age and medical history.&#xD;
Baloxavir Marboxil: Individuals willing and able, will receive a weight-based oral dose of baloxavir within 48 hours of symptom onset</description>
        </group>
        <group group_id="P2">
          <title>Study Drug Ineligible</title>
          <description>Individuals not eligible to receive on-label use of Baloxavir due to age or medical history</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="302"/>
                <participants group_id="P2" count="179">The 179 individuals that were not eligible to receive the study drug, participated in an observation portion of the study where all study procedures were the same excluding telehealth visit and an antiviral delivery.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="302"/>
                <participants group_id="P2" count="179"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Based on individuals that contributed data during the test-and-treat phase of the protocol.</population>
      <group_list>
        <group group_id="B1">
          <title>Study Drug Eligible</title>
          <description>Baloxavir given in 40 mg and 80 mg tablets for single-dose oral consumption during the first influenza infection for that participant&#xD;
Baloxavir Marboxil: Individuals willing and able, will receive a weight-based oral dose of baloxavir within 48 hours of symptom onset</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="481"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="221"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="250"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="253"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="439"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="408"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="481"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Initiate Antiviral Therapy Within 48 Hours of Symptom Onset</title>
        <description>Among symptomatic participants, this outcome measure will be calculated by determining the number of home influenza test-positive, drug eligible participants that were prescribed and rapidly delivered baloxavir by the study within 48 hours of symptom onset.</description>
        <time_frame>Up to 48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Drug Eligible</title>
            <description>Baloxavir given in 40 mg and 80 mg tablets for single-dose oral consumption during the first influenza infection for that participant&#xD;
Baloxavir Marboxil: Individuals willing and able, will receive a weight-based oral dose of baloxavir within 48 hours of symptom onset</description>
          </group>
        </group_list>
        <measure>
          <title>Initiate Antiviral Therapy Within 48 Hours of Symptom Onset</title>
          <description>Among symptomatic participants, this outcome measure will be calculated by determining the number of home influenza test-positive, drug eligible participants that were prescribed and rapidly delivered baloxavir by the study within 48 hours of symptom onset.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Home Influenza Tests Confirmed by Laboratory Testing</title>
        <description>Proportion of individuals who test positive for influenza using the home-based influenza test compared to the number of individuals that test positive for influenza via a PCR laboratory test</description>
        <time_frame>Up to 48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Drug Eligible</title>
            <description>Baloxavir given in 40 mg and 80 mg tablets for single-dose oral consumption during the first influenza infection for that participant&#xD;
Baloxavir Marboxil: Individuals willing and able, will receive a weight-based oral dose of baloxavir within 48 hours of symptom onset</description>
          </group>
        </group_list>
        <measure>
          <title>Home Influenza Tests Confirmed by Laboratory Testing</title>
          <description>Proportion of individuals who test positive for influenza using the home-based influenza test compared to the number of individuals that test positive for influenza via a PCR laboratory test</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Delivered Antivirals Within 48 Hours of Symptom Onset</title>
        <description>Proportion of individuals who are delivered antivirals within 48 hours of symptom onset. Only drug eligible study participants prescribed an antiviral</description>
        <time_frame>Up to 48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Drug Eligible</title>
            <description>Baloxavir given in 40 mg and 80 mg tablets for single-dose oral consumption during the first influenza infection for that participant&#xD;
Baloxavir Marboxil: Individuals willing and able, will receive a weight-based oral dose of baloxavir within 48 hours of symptom onset</description>
          </group>
        </group_list>
        <measure>
          <title>Delivered Antivirals Within 48 Hours of Symptom Onset</title>
          <description>Proportion of individuals who are delivered antivirals within 48 hours of symptom onset. Only drug eligible study participants prescribed an antiviral</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 days after receipt of antiviral</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Study Drug Eligible</title>
          <description>Baloxavir given in 40 mg and 80 mg tablets for single-dose oral consumption during the first influenza infection for that participant&#xD;
Baloxavir Marboxil: Individuals willing and able, will receive a weight-based oral dose of baloxavir within 48 hours of symptom onset</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Research Coordinator</name_or_title>
      <organization>University of Washington</organization>
      <phone>2066165859</phone>
      <email>jheimo@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

